Search

Objectives To investigate the efficacy and prognosis of low molecular weight heparin (LMWH) in the treatment for the patients with chronic cor pulmonale during acute attack. Methods 320 cases patients with chronic cor pulmonale during acute attack, were at random divided into study group (167 cases) and control group (153 cases) all the patients in two groups were given the same routine treatments such as anti-infection, expectorant, relieving spasm, balancing hydro-electrolytic disorder, low flow oxygen inhalation, and conventional digitals, diuretics, vasodilators therapy. In study group, besides routine treatment, low molecular weight heparin (LMWH) was given. compared clinical features, laboratory results in the two groups before and after the treatment. We followed up these cases during 90 days after treatment, the patients in both groups were observed for comparison of the clinical effect, major adverse events rate, complication, stroke and the death of 90 days. Results Clinical features, laboratory results in study group were markedly improved after the treatment than those in control group (91% VS 82%) (P Conclusions Low molecular weight heparin (LMWH) was effective to the patients with chronic cor pulmonale during acute attack.

Objectives To evaluate the effects of AVE0991 on vascular remodelling in vein grafts. Methods A model of autologous jugular vein grafts in rats was established. With this model system, rats (n = 16 per group) underwent autologous jugular vein graft transplantation (AVE0991 and control groups), or a sham operation (sham group) in which grafting was not performed. Three days after operation, all rats were treated with AVE0991(1mg/kg/d) (AVE0991 group) or PEG-400(0.5ml/d) (control and sham groups) by adminstration. Results After 4 weeks, weight, blood pressure and heart rate were not significantly different between groups. Typical venous-graft hyperplasia, vascular remodelling, ERK1/2 activity, p38 MAPK activity and proliferating cell nuclear antigen (PCNA) and a-smooth muscle actin (a-SMA) expression present in the control group were attenuated by AVE0991 treatmen. Tissue angiotensin II expression was increased in the AVE0991 and control groups but was not different between the groups. Conclusions The results of the present study indicate that AVE0991 interferes with the vascular remodelling of autologous jugular vein grafts and significantly inhibits vein-graft intimal hyperplasia via inhibition of vascular tissue ERK1/2 and p38 MAPK activation. Thus, AVE0991 improves the outcome of vein grafting via attenuation of vascular remodelling.

Objectives To investigate the effect of Shenmai injection on the therapeutic effect and cardiac function and brain natriuretic peptide (BNP) in gerontal patient with chronic heart failure. Methods 64 patients age more than 65 years with chronic heart failure were randomly divided into two groups: the treatment group (n=34) and control group (n=30). Patients in the control group were given routine therapy including oxygen inhaling, cardiotonic, diuresis, blood vessels extension, correcting the fluid and electrolyte imbalance, and the patients in the treatment group were given Shenmai injection 100 ml every day underlying the routine therapy. The course of treatment was 4 weeks. Observe the NYHA class, left ventricular end diastolic diameters (LVEDD), left ventricular ejection fraction (LVEF), cardiac output (CO), stroke volume (SV) and serum BNP of the patients before and after treatment. Results Every index of cardiac function and BNP of patients in two groups were significantly improved (p 0.05). Conclusions Shenmai injection association with routine treatment can improve the therapeutic effect and cardiac funtion of the gerontal patients with chronic heart failure.

Objectives Patients admitted to our ER and CCU from November 2007 to February 2008. Consisting of 11 patients, 7 males and 4 females, mean age 61.44±13.70 years with a range from 33 to 75 years. All cases are diagnosed based on the AMI diagnosis criteria under Chinese Medical Association in 1999, For patients with normal controls with age, sex matching healthy volunteers 10 people, 7 male and 3 female, the average age 53.00±6.55 (32–61). Acute onset in STEMI group hospital diagnosed after extracting cubits 10 ml were immediately into containing 0.05 ml of heparin without bacteria. After acute onset of emergency PCI and conventional treatment, the third day and the seventh day each pump once again were cubits 10 ml; The comparison group: morning, fasting extraction method 10 ml were cubits under the same approach as that for the patients group. PBMCs separation adopts the lymphocyte separate liquid density gradient centrifugation. Using Human Stress & Toxicity Pathway Finder PCR Array screening method of myocardial IRI related gene changes. The validation of expression of CYP1A1 TNFSF6 by Real time PCR. All data to differences with mean±SD, Value of patients and controls were compared by ANOVA analysis. And correlation analysis method, the related to p Methods Patients admitted to our ER and CCU from November 2007 to February 2008. Consisting of 11 patients, 7 males and 4 females, mean age 61.44±13.70 years with a range from 33 to 75 years. All cases are diagnosed based on the AMI diagnosis criteria under Chinese Medical Association in 1999, For patients with normal controls with age, sex matching healthy volunteers 10 people, 7 male and 3 female, the average age 53.00±6.55 (32–61). Acute onset in STEMI group hospital diagnosed after extracting cubits 10 ml were immediately into containing 0.05 ml of heparin without bacteria. After acute onset of emergency PCI and conventional treatment, the third day and the seventh day each pump once again were cubits 10 ml; The comparison group: morning, fasting extraction method 10 ml were cubits under the same approach as that for the patients group. PBMCs separation adopts the lymphocyte separate liquid density gradient centrifugation. Using Human Stress & Toxicity Pathway Finder PCR Array screening method of myocardial IRI related gene changes. The validation of expression of CYP1A1 TNFSF6 by Real time PCR. All data to differences with mean±SD, Value of patients and controls were compared by ANOVA analysis, and correlation analysis method, the related to p Results 1. Of the STEMI group, general average STEMI genes that significant changes in 14, which were up regulated the gene expression of significant for 8, were significant down regulated for four genes. The genes expression were up regulated which are cell growth/aging related genes1 (GADD45A), oxidation stress and metabolic related gene 1 (PRDX2), Heat shock related gene 3 (HSPD1, DNAJB1, DNAJB2), and repair DNA damage related gene 1 (RAD50), and apoptosis signal related gene 2 (TNFSF6 TRADD,) Significant down regulated of those genes: the cell proliferation/cancer related gene 1 (CCNG1), oxidation or metabolic stress related gene gene 2 (CAT, CYP1A1), DNA damage and restoration related gene 1 (ATM). 2. The expression of TNFSF6 in STEMI group is higher than of the healthy group and CYP1A1 was lower than the normal value. Conclusions 1. The moderation of multiple genes resulting from myocardial IRI due to after PCI with acute myocardial infarction. It provides a more complete view in the complication and complexity of myocardial IRI gene regulation. 2. The quantitative analysis of TNFSF6 and CYP1A1 genes after myocardial IRI in AMI at various stage. They may be involved in the myocardial ischaemia/reperfusion injury physiopathological process.

Objectives To evaluate the effect of different dose of anticoagulants in haemodialysis patients with acute coronary syndrome (not including ST-elevate myocardial infarction). Methods 28 patients with ACS (not including ST-elevate myocardial infarction) were enrolled between March 2008 and March 2012 who started haemodialysis for 5–10 years in regular pattern. The patients were randomly divided into two groups: the routine group (n=12) and strengthen group (n=16). All patients were given routine therapy including regular haeparinised haemodialysis (three times a week), rest, oxygen inhaling, antiplatelet, reducing blood lipid levels, controlling the blood pressure. The patients in the routine group were given the factor X a inhibitor fondaparinux 2.5 mg every day except the haemodialysis days. The patients in the strengthen group were given fondaparinux 2.5 mg every day including the haemodialysis days. The course of treatment was 7 days. Observe the symptom, electrocardiogram, cardiac troponin T, coagulation function (PT, APTT, INR) for 14 days. Results One patient in routine group was died of heart failure, another patients in strengthen group exited because of gastrointestinal bleeding. The basic characteristics of the two groups were identical (p>0.05). Patients9 symptom relieved in (3.1±2.8) days in strengthen group and (5.0±3.6) days in routine group (p Conclusions Strengthen anticoagulant therapy in haemodialysis patients with acute coronary syndrome (not including ST-elevate myocardial infarction) is more effective than routine therapy, but we must be care of the risk of haemorrhage.

Objects To evaluate the effects of Ang-(1-7) on vascular remodelling in vein grafts. Methods a model of autologous jugular vein grafts in rats was established. With this model system, rats (n=12 per group) underwent autologous jugular vein graft transplantation (Ang-(1-7) and control groups), or a sham operation (sham group) in which grafting was not performed. Three days after operation, minipumps were installed for continuous infusion of Ang-(1-7) (25 μg/kg/h) or normal saline (control and sham groups) through the jugular vein. Results 4 weeks, weight, blood pressure and heart rate were not significantly different between groups. Typical venous-graft hyperplasia, vascular remodelling, ERK1/2 activity, p38 MAPK activity and proliferating cell nuclear antigen (PCNA) and a-smooth muscle actin (a-SMA) expression present in the control group were attenuated by continuous Ang-(1-7) infusion. Tissue angiotensin II expression was increased in the Ang-(1-7) and control groups but was not different between the groups. Conclusion The results of the present study indicate that exogenous Ang-(1-7) interferes with the vascular remodelling of autologous jugular vein grafts and significantly inhibits vein-graft intimal hyperplasia via inhibition of vascular tissue ERK1/2 and p38 MAPK activation. Thus, exogenous Ang-(1-7) improves the outcome of vein grafting via attenuation of vascular remodelling.

Understand the changes in the genes of oxidative stress and the process of cell toxic with myocardial IRI due to before and after operative of PCI in STEMI patients. Observe in a dynamic environment the changes in the mRNA expression of TNFSF6 and CYP1A1 resulting from myocardial IRI and clinical